{
    "2018-08-01": [
        [
            {
                "time": "",
                "original_text": "十年磨一剑，哪些股票穿越牛熊？",
                "features": {
                    "keywords": [
                        "长期投资",
                        "牛熊市",
                        "股票"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "2018中国上市公司最佳CEO榜单公布 9家药企高管榜上有名",
                "features": {
                    "keywords": [
                        "CEO",
                        "榜单",
                        "药企",
                        "高管"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[增持评级] 昭衍新药(603127)简评：业绩维持高速增长 订单及产能带动增量",
                "features": {
                    "keywords": [
                        "昭衍新药",
                        "增持评级",
                        "业绩增长",
                        "订单",
                        "产能"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "前7月偏股型基金业绩排名出炉 医药基金继续领跑",
                "features": {
                    "keywords": [
                        "偏股型基金",
                        "业绩排名",
                        "医药基金"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "[买入评级] 小分子靶向药物(医药生物行业)：医保谈判催化 竞争格局生变",
                "features": {
                    "keywords": [
                        "小分子靶向药物",
                        "买入评级",
                        "医保谈判",
                        "竞争格局"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "专访 | 恒瑞张连山：立项要理性，BD要“舍得交学费”",
                "features": {
                    "keywords": [
                        "恒瑞",
                        "张连山",
                        "立项",
                        "BD",
                        "理性",
                        "学费"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}